Publicacións nas que colabora con Nieves Purificacion Martinez Lago (10)

2022

  1. Efficacy and safety of FOLFIRI/aflibercept (FA) in an elderly population with metastatic colorectal cancer (mCRC) after failure of an oxaliplatin-based regimen

    PLoS ONE, Vol. 17, Núm. 6 June

  2. Efficacy, safety and prognostic factors in patients with refractory metastatic colorectal cancer treated with trifluridine/tipiracil plus bevacizumab in a real-world setting

    Scientific Reports, Vol. 12, Núm. 1

2021

  1. Do clinical trials meet current care needs? Views of digestive oncology specialists in galicia (spain) using the delphi method

    Healthcare (Switzerland), Vol. 9, Núm. 6

  2. Effect of antiangiogenic-based treatment and systemic inflammatory factors on outcomes in patients with BRAF v600-mutated metastatic colorectal cancer: a real-world study in Spain

    BMC Cancer, Vol. 21, Núm. 1

  3. Prediction of survival in patients with advanced, refractory colorectal cancer in treatment with trifluridine/tipiracil: real-world vs clinical trial data

    Scientific Reports, Vol. 11, Núm. 1

2020

  1. Efficacy and safety of trifluridine/tipiracil in third-line and beyond for the treatment of patients with metastatic colorectal cancer in routine clinical practice: patterns of use and prognostic nomogram

    Clinical and Translational Oncology, Vol. 22, Núm. 3, pp. 351-359

2019

  1. Efficacy and safety of FOLFIRI/Aflibercept (FA) in an elderly population with metastatic colorectal cancer (mCRC) after the failure of an oxaliplatin-based regimen

    Annals of Oncology, Vol. 30, pp. iv42-iv43

  2. Efficacy and safety of FOLFIRI/aflibercept in second-line treatment of metastatic colorectal cancer in a real-world population: Prognostic and predictive markers

    Cancer Medicine, Vol. 8, Núm. 3, pp. 882-889

  3. Is there any affordable and reliable score in local gastric cancer?

    Annals of Oncology, Vol. 30, pp. iv60

2018

  1. Differences in outcome according to chemotherapy backbone and maintenance treatment in HER2 positive metastatic gastric cancer (GC) or gastroesophageal junction (GEJ)

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii225